Anti-Coagulants - Myanmar

Myanmar

The Anti-Coagulants market in Myanmar is expected to achieve a revenue of US$6.87m by 2024.
This projection indicates a consistent annual growth rate (CAGR 2024-2029) of 7.45%, which will ultimately lead to a market volume of US$9.84m by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$16,740.00m in 2024.
Myanmar's anti-coagulant market is experiencing significant growth due to the increasing prevalence of cardiovascular diseases in the country.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Myanmar has seen significant growth in recent years.

Customer preferences: There is a growing demand for Anti-Coagulants in Myanmar due to the increasing prevalence of cardiovascular diseases and stroke. Patients are becoming more aware of the benefits of Anti-Coagulants in reducing the risk of blood clots and preventing strokes. Additionally, an aging population is also contributing to the growth of the market.

Trends in the market: The Anti-Coagulants market in Myanmar is dominated by oral anticoagulants, with a preference for newer agents such as direct oral anticoagulants (DOACs) over traditional anticoagulants such as warfarin. This trend is in line with the global market, where DOACs are becoming increasingly popular due to their convenience and reduced risk of bleeding.

Local special circumstances: Myanmar has a relatively underdeveloped healthcare system, which presents both challenges and opportunities for the Anti-Coagulants market. On the one hand, limited access to healthcare facilities and a lack of awareness about the benefits of Anti-Coagulants may hinder market growth. On the other hand, the government's efforts to improve healthcare infrastructure and increase healthcare spending may create new opportunities for market expansion.

Underlying macroeconomic factors: Myanmar's economy is growing rapidly, with a projected GDP growth rate of 6.8% in 2021. This is driving increased investment in the healthcare sector, including the Anti-Coagulants market. However, political instability and ongoing conflicts in some parts of the country may pose a risk to market growth in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.